Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim of this study was to test the new Direct Flow Medical system, which is more flexible prosthesis with a lower profile that could result in minor aortic regurgitation and less need for post expansion. This multicenter study included<a href="https://solaci.org/en/2015/06/24/salus-new-percutaneous-valve-with-promising-results-regarding-aortic-regurgitation-post-implant/" title="Read more" >...</a>

Severe mitral regurgitation is three times more prevalent than aortic stenosis in the elderly population at high risk and poor prognosis if not treated. Fortis mitral valve was designed using several preclinical models and are now tested for the first time in 4 patients resulting in various technical difficulties and finally the death of 3<a href="https://solaci.org/en/2015/06/24/mitral-first-cases-of-transcatheter-mitral-valve-implantation-tmvi/" title="Read more" >...</a>

TVT STS / ACC registrywas developed to obtain data from all patients undergoing percutaneous aortic valve replacement (TAVR) in the United States. The clinical outcome at 30 days was recently published (Macket al, JAMA 2013) but there are few data on the longer-term treatment that is already incorporated in clinical practice in the United States.The<a href="https://solaci.org/en/2015/06/24/american-registry-for-percutaneous-aortic-valve-replacementone-year-evolution-of-nearly-6000-patients/" title="Read more" >...</a>

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area &lt; 0.8 cm2 , valvular index &le; 0.5 cm2 , a mean gradient of &nbsp;&gt; 40 mmHg or peak speeds above 4m /s<a href="https://solaci.org/en/2015/06/24/corevalve-superior-to-surgical-aortic-valve-replacement-in-high-risk-patients/" title="Read more" >...</a>

So far, there had been no published randomized studies comparing balloon-expandable Edwards&rsquo;s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in<a href="https://solaci.org/en/2015/06/24/choice-trial-same-mortality-less-aortic-regurgitation-and-need-for-a-second-prosthetic-for-edwards-sapien-xt-valve-versus-medtronic-corevalve/" title="Read more" >...</a>

Unlike degenerative mitral insufficiency, ischemic failure is due to an increase in the left ventricular cavity, the loss of its elliptical form, ring dilation and displacement of the papillary muscles leading to the loss of coaptation the leaflets. European and American guidelines suggest the intervention on the mitral valve in patients with ischemic mitral regurgitation<a href="https://solaci.org/en/2015/06/24/plastic-versus-mitral-valve-replacement-in-ischemic-mitral-regurgitation/" title="Read more" >...</a>

Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant in 2011 were included. As recommended in the European Cardiovascular Guidelines, this national registry suggests that percutaneous implant represents the dominant treatment of this disease, especially in high-risk patients. In high-risk<a href="https://solaci.org/en/2015/06/24/gary-german-aortic-valve-registry/" title="Read more" >...</a>

Magnus Seergren2013-08-21

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received the device and were followed during 30 days. Mortality from all causes was 1.7% and the incidence of stroke was 8.6%, with half<a href="https://solaci.org/en/2015/06/24/reprise-ii-results-obtained-with-the-new-valve-according-to-varc-criteria/" title="Read more" >...</a>

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve device in patients with severe aortic stenosis and high surgical risk. The device is designed to reduce post-implant aortic regurgitation; it has a low profile and high navigability and requires no post-dilatation or rapid pacing. The study included<a href="https://solaci.org/en/2015/06/24/discover-new-low-profile-valve-with-little-post-implant-regurgitation/" title="Read more" >...</a>